Subject(s)
Broad Ligament , Leiomyoma/diagnosis , Lipoma/diagnosis , Uterine Neoplasms/diagnosis , Aged , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Leiomyoma/pathology , Leiomyoma/surgery , Lipoma/pathology , Lipoma/surgery , Middle Aged , Paraffin Embedding , Uterine Neoplasms/pathology , Uterine Neoplasms/surgerySubject(s)
Nasopharyngeal Diseases/diagnosis , Tuberculosis, Lymph Node/diagnosis , Tuberculosis/diagnosis , Aged , Antitubercular Agents/therapeutic use , Diagnosis, Differential , Endoscopy , Female , Humans , Nasopharyngeal Diseases/drug therapy , Nasopharyngeal Neoplasms/diagnosis , Tomography, X-Ray Computed , Tuberculosis/drug therapy , Tuberculosis, Lymph Node/drug therapyABSTRACT
We attempted to determine Bcl-2, inducible nitric oxide synthase (iNOS), p53 and proliferating cell nuclear antigen (PCNA) expression, and the relationships between them, in endometrioid adenocarcinomas and precursor lesions. Expression of Bcl-2, iNOS, p53 and PCNA were investigated immunohistochemically in 91 samples from benign (proliferative (pEM), secretory (sEM), disordered proliferative (dEM), inactive/atrophic (aEM), hyperplastic endometrium) and malignant endometrial tissue. Staining scores for Bcl-2 in the dEM, endometrial hyperplasia (EMH) and endometrioid cancer (ECA) groups were higher than in the pEM group (P = 0.004; P = 0.036 and P = 0.020, respectively). A significant difference in proliferating cell nuclear antigen staining was found between simple and complex EMH samples (P = 0.000). An inverse relationship was found between iNOS and p53 in the hyperplasia group (r = -0.533, P = 0.019). While a significant difference was found in p53 staining in ECA between the pEM, dEM and EMH groups, no such difference was found in iNOS staining. In addition, there was no direct relationship between iNOS and p53 in the ECA group. It was concluded that the interaction between iNOS, p53 and Bcl-2 in proliferative processes in the development of type 1 endometrioid adenocarcinomas is different from that in tumors originating in other organs.
Subject(s)
Adenocarcinoma/metabolism , Endometrial Neoplasms/metabolism , Nitric Oxide Synthase/biosynthesis , Proliferating Cell Nuclear Antigen/biosynthesis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Tumor Suppressor Protein p53/biosynthesis , Adenocarcinoma/pathology , Endometrial Hyperplasia/metabolism , Endometrial Hyperplasia/pathology , Endometrial Neoplasms/pathology , Endometrium/pathology , Female , Humans , Immunohistochemistry , Nitric Oxide Synthase Type IIABSTRACT
Recently, some studies reported the presence of mast cells in various malignancies and their role in tumor growth. The aim of the study was to determine the utility of mast cell numbers in evaluating benign and malignant prostate lesions, and to ascertain whether there are variations in the numbers of mast cells with the Gleason grade. The relationship between mast cell numbers and patient age was also investigated. Retrospectively, 104 prostate specimens were examined for the presence of mast cells. The study group consisted of 57 benign prostatic hyperplasias and 47 prostate carcinomas. The paraffin sections were stained with anti-human mast cell tryptase immunohistologically. The numbers of positively staining cells in five high-power fields were counted, and their mean was calculated. There was no relationship found between mast cell numbers and age statistically. The mean mast cell numbers of the intratumoral region were significantly different from those of the peritumoral region (p = 0.0001). While the difference between benign hyperplasia and the intratumoral region was found to be significant (p = 0.0001), no difference between hyperplasia and the peritumoral region was noted (p = 0.762). There was no statistical difference between Gleason score groups (p = 0.452), and there was no interaction between score groups and intraperitumoral regions (p = 0.355).
